Navigation Links
Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/5/2010

on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.Halozyme ContactRobert H. UhlSenior Director, Investor Relations(858) 704-8264ruhl@halozyme.comHalozyme Therapeutics, Inc.Condensed Consolidated Statements of OperationsThree Months EndedNine Months EndedSeptember 30, September 30,2010200920102009(unaudited)(unaudited)(unaudited)(unaudited)REVENUES:Product sales

$
98,100$
411,109$
95,440$
9,267Revenues under collaborative agreements

3,298,4072,617,7769,356,1516,558,145Total revenues

3,396,5073,028,88510,051,5917,227,412OPERATING EXPENSES:Cost of product sales

7,214102,63896,413151,939Research and development

12,448,86513,162,74835,840,47541,763,972Selling, general and administrative

3,374,0693,703,09910,488,56811,093,563Total operating expenses

15,830,14816,968,48546,425,45653,009,474OPERATING LOSS

(12,433,641)(13,939,600)(36,373,865)(45,782,062)Interest and other income, net

24,06529,31825,88986,391NET LOSS

$ (12,409,576)$ (13,910,282)$ (36,347,976)$ (45,695,671)Basic and diluted net loss per share

$
(0.13)$
(0.16)$
(0.39)$
(0.54)Shares used in computing basic and dilutednet loss per share

93,626,89389,570,54092,342,66585,086,456Halozyme Therapeutics, Inc.Condensed Consolidated Balance SheetsSeptember 30,December 31,20102009(unaudited)ASSETSCurrent assets:Cash and cash equivalents

$
89,840,588$   67,464,506Accounts receivable

2,622,0764,243,909Inventory

1,076,5801,159,551Prepaid expenses and other assets

4,891,5561,573,777Total current assets

98,430,80074,441,743Property and equipment, net

1,960,9352,708,016Total Assets

$   100,391,735$   77,149,759LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

$
,828,069$
2,820,491Accrued expenses

5,052,7236,083,854Deferred revenue

4,900
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
10. Halozyme Receives $5.5 Million Payment From Baxter
11. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013   NineSigma , Inc., of ... following its launch, NineSights.com is now the ... for the worldwide community of innovators. From ... sustainability experts, NineSights stands out for its large community ... and technical disciplines, all vetted by NineSigma. The community ...
(Date:6/19/2013)... Atlanta (PRWEB) June 19, 2013 Today ... urged young people to become leaders in the greatest ... 9 billion people in 2050. Borel spoke at ... Conference in Atlanta, about urgent need for students ... that are local, science-based, sustainable and reached in collaboration ...
(Date:6/19/2013)... June 19, 2013 ... presents Innovative Drug Delivery Systems: ... Licensing Opportunities for Generic Pharmaceutical ... There are more than ... drugs approved all over the ...
(Date:6/19/2013)... India’s vast and growing population means ... up to a billion dollars per year by ... taking serious action to better regulate and oversee ... will examine:, ,     Recent changes in ... long term impacts ,     Foreseeable opportunities ...
Breaking Biology Technology:NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3DuPont Leader Calls for New Generation of Food Visionaries to Fight Hunger 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3
... revolutionary surgical instrument system that is smaller in diameter than a ... implantation of the VerteLoc™ Minimally Invasive Spine Stabilization System and will ... Arizona starting on March 12, 2009. , ... Winston-Salem, ...
... In ClearTrial v2.7, the newest version of ... Portfolio Planning capability which enables clinical development ... into portfolio-level forecasts in minutes. The ... monthly resource demand, and timelines across a ...
... Enobia Pharma, an emerging Canadian biotech company ... disorders, today announced completion of target enrollment in ... a severe form of hypophosphatasia. Enobia is ... the treatment of this rare and often crippling ...
Cached Biology Technology:VGI Announces the Launch of DISMISS Instruments for the VerteLoc™ Minimally Invasive Spine Stabilization System 2ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 2ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 3ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 4Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia 2Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia 3
(Date:6/19/2013)... Medicines Agency (EMA) approved the modified adeno-associated virus ... for clinical use in the Western world. uniQure, ... for the treatment of a rare inherited metabolic ... approximately one or two out of one million ... the pancreas. Afflicted individuals carry a defect in ...
(Date:6/18/2013)... from the United Kingdom, the Energy Department,s National ... Kentucky have recently published a paper describing a ... Limnoria quadripunctata , commonly known as the ... they exhibit a relatively unique ability to produce ... to break down the biomass they eat. New ...
(Date:6/18/2013)... of Molecular Biology, has been honored as a ... Torrent is being recognized for his outstanding research, ... antimicrobial regions in proteins. Luis Rivas, Centro de ... algorithm to interrogate full genomes in order to ... results." , Torrent obtained his Ph.D. from ...
Breaking Biology News(10 mins):No danger of cancer through gene therapy virus 2Novel enzyme from tiny gribble could prove a boon for biofuels research 2The American Society for Microbiology honors Marc Torrent 2
... an inherited genetic basis for racial and ethnic disparities ... increased risk of relapse in young leukemia patients. The ... Research Hospital and the Children,s Oncology Group (COG). ... new marker of poor treatment outcome, researchers reported evidence ...
... N.C. Everyone knows chocolate is critical to a happy Valentine,s ... a heart happy the rest of the year. It,s a ... DOT1L enzyme, you could be at risk for some types of ... the University of North Carolina at Chapel Hill School of Medicine ...
... Reserve University have developed a little bomb that promises a ... an anti-cancer drug loosely attached to gold nanoparticles starts accumulating ... activated for an effective treatment within two hours. The same ... the tumor from the surface a far less effective ...
Cached Biology News:Native American ancestry linked to greater risk of relapse in young leukemia patients 2Native American ancestry linked to greater risk of relapse in young leukemia patients 3Just in time for Valentine's Day: UNC researchers identify a gene critical for heart function 2A loose grip provides better chemotherapy 2
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
WTAP Antibody...
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: